Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Germ Line

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Germ Line. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-000618-35 Sponsor Protocol Number: M07PGC Start Date*: 2007-11-29
    Sponsor Name:Rigshospitalet
    Full Title: PHASE II TRIAL OF PACLITAXEL, GEMCITABINE AND CISPLATIN IN PATIENTS WITH RELAPSING GERM CELL CANCER AFTER FIRST LINE CHEMOTHERAPY
    Medical condition: · The primary objective of this study is to investigate the combination of cisplatin/gemcitabine/paclitaxel, with respect to progression free survival in patients with germ cell tumours previously...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing) DK (Ongoing) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004508-36 Sponsor Protocol Number: FM-12-GCT01 Start Date*: 2013-05-04
    Sponsor Name:Fondazione Michelangelo - Avanzamento dello studio e cura dei tumori
    Full Title: Brentuximab vedotin (SGN-35) as salvage therapy for males with advanced and platinum-resistant germ-cell tumors. An open label, single group, Phase 2 trial
    Medical condition: Patients with histologically-confirmed germ-cell cancer with exclusive or prevalent CD30-positive embryonal carcinoma component
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061378 Testicular germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021898-36 Sponsor Protocol Number: INT 38/10 Start Date*: 2010-10-20
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Tandem high-dose chemotherapy (HDCT) with peripheral-blood stem-cell rescue for patients with metastatic germ-cell tumors failing first-line treatment.
    Medical condition: Patients with metastatic germ-cell tumors failing first-line treatment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043302 LLT
    9.1 10061378 LLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004910-33 Sponsor Protocol Number: PAZOTEST-01 Start Date*: 2012-12-24
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study of single-agent Pazopanib (Votrient) for patients with relapsed or refractory germ-cell tumors (GCT).
    Medical condition: Testicular or extragonadal germ cell tumors.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10018187 Genitourinary neoplasms malignancy and gender unspecified HLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003930-17 Sponsor Protocol Number: 1407-GUCG Start Date*: 2015-10-05
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLO...
    Medical condition: progressive or recurrent germ cell tumor (measurable or non-measurable)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10043338 Testicular malignant germ cell tumor NOS LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: BE (Ongoing) DK (Ongoing) IE (Ongoing) FR (Ongoing) NL (Ongoing) SI (Completed) ES (Ongoing) DE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003060-37 Sponsor Protocol Number: ANZUP1302 Start Date*: 2017-04-05
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: UK P3BEP - A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
    Medical condition: International germ cell classification catergory (IGCCC) intermediate or poor-risk metastatic germ cell tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068971 Germ cell cancer metastatic PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-001270-33 Sponsor Protocol Number: GCTSK003 Start Date*: 2015-07-28
    Sponsor Name:Národný onkologický ústav
    Full Title: A treatment strategy of the Use of 1st line Chemotherapy in Patients with Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors based on tumor marker decline: A Phase II Trial of paclitaxel...
    Medical condition: Disseminated Non-Seminomatous Germ Cell Tumors.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004039-60 Sponsor Protocol Number: ET13-016 Start Date*: 2014-10-23
    Sponsor Name:CENTRE LEON BERARD
    Full Title: A multicenter study to evaluate a risk-adapted strategy for treatment of extra cranial non seminomateous malignant germ cell tumour in children, adolescent and young adult
    Medical condition: extra cranial non seminomateous malignant germ cell tumour in child, adolescent and young adult
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10049516 Malignant tumor LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003336-37 Sponsor Protocol Number: HBA_001 Start Date*: 2018-06-25
    Sponsor Name:SGHL – SOCIEDADE GESTORA DO HOSPITAL DE LOURES, S.A - Hospital Beatriz Ângelo
    Full Title: CA2209-9G7: Phase II multi-institutional proof of concept single-arm trial of Nivolumab in the treatment of patients with platinum-recurrent or platinum-refractory metastatic germ cell tumors
    Medical condition: Metastatic germ cell tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005325-30 Sponsor Protocol Number: D8180C00015 Start Date*: 2008-04-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-Blind, Placebo Controlled, Multi-Centre, Randomised Study of AZD0530 in Patients with Advanced Ovarian Cancer Sensitive to Platinum-Based Chemotherapy
    Medical condition: advanced ovarian cancer sensitive to platinum based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033129 Ovarian neoplasms malignant (excl germ cell) HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) FR (Completed) DK (Completed) PT (Completed) BG (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002805-36 Sponsor Protocol Number: ENGOT-OV30/NSGO Start Date*: 2017-10-23
    Sponsor Name:NSGO
    Full Title: NSGO-OV-UMB1; ENGOT-OV30: A phase II umbrella trial in patients with relapsed ovarian cancer.
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033129 Ovarian neoplasms malignant (excl germ cell) HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) FI (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2014-003773-42 Sponsor Protocol Number: PM1183-B-005-14 Start Date*: 2015-03-30
    Sponsor Name:Pharma Mar S.A. Sociedad Unipersonal
    Full Title: A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors.
    Medical condition: Selected Advanced Solid Tumors.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000309-75 Sponsor Protocol Number: Start Date*: 2005-08-26
    Sponsor Name:Christian Geisler, Rigshospitalet, dept. Haematology 4042
    Full Title: HOVON 68 CLL: A randomized phase III study in prevously untreated patients with biological high risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab.
    Medical condition: Chronic lymphocytic leukaemia (CLL) in biological high-risk group: Unmutated and/or with deletion 17p and/or deletion 11q and/or trisomy 12.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing) SE (Ongoing) FI (Completed) BE (Ongoing) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002949-42 Sponsor Protocol Number: PACT-29 Start Date*: 2020-11-27
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing a germ line BRCA or other DNA Defects Repair (DDR) mutations.
    Medical condition: Patients affected by metastatic pancreatic adenocarcinoma (PDAC).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052747 Adenocarcinoma pancreas PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000109-10 Sponsor Protocol Number: UNITO-001/2020 Start Date*: 2020-09-30
    Sponsor Name:DIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO
    Full Title: A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive fo...
    Medical condition: patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germ or somatic mutations in DNA damage repair genes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062042 Lung neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10045155 Tumor of pleura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001852-23 Sponsor Protocol Number: M14ABC Start Date*: 2017-09-29
    Sponsor Name:NKI-AVL
    Full Title: A feasibility study of niraparib for advanced, BRCA1-like, HER2-negative breast cancer patients
    Medical condition: Breast cancer, advanced
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002966-37 Sponsor Protocol Number: 1-2018BSMO Start Date*: 2019-01-23
    Sponsor Name:Belgian Society of Medical Oncology
    Full Title: Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes.
    Medical condition: Advanced cancer patients that have a germline mutation or a somatic mutation in their tumor. Prostate and ovarian cancer patients and breast cancer patients who carry a BRCA1/2 mutation will be exc...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003706-40 Sponsor Protocol Number: PAZOBONE Start Date*: 2017-11-28
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: PAZOBONE: First line treatment with Pazopanib in untreated metastatic renal cell carcinoma patients with bone involvement
    Medical condition: Patients affected by untreated metastatic renal cell carcinoma with bone involvement
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073251 Clear cell renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003176-16 Sponsor Protocol Number: ADP-0055-003/GOG-3084 Start Date*: 2023-05-03
    Sponsor Name:Adaptimmune LLC
    Full Title: A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084)
    Medical condition: Recurrent ovarian cancer positive for MAGE-A4 in human leukocyte antigen (HLA)-A2+ subjects
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000428-12 Sponsor Protocol Number: CLEE011X2201 Start Date*: 2014-10-24
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A randomized, blinded, placebo-controlled, phase II trial of LEE011 in patients with relapsed, refractory, incurable teratoma with recent progression
    Medical condition: relapsed, refractory, incurable teratoma
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) FR (Prematurely Ended) NL (Temporarily Halted) DK (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:11:22 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA